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a b s t r a c t
Evidence is emerging for a role for neurotrophins in the treatment of mood disorders. In this study,
we evaluated the effects of chronic administration of ﬂuoxetine, olanzapine and the combination of
ﬂuoxetine/olanzapine on the brain-derived-neurotrophic factor (BDNF), nerve growth factor (NGF), and
neurotrophin-3 (NT-3) in the rat brain. Wistar rats received daily injections of olanzapine (3 or 6mg/kg)
and/or ﬂuoxetine (12.5 or 25mg/kg) for 28 days, and we evaluated for BDNF, NGF and NT-3 protein
levels in the prefrontal cortex, hippocampus and amygdala. Our results showed that treatment with
ﬂuoxetine and olanzapine alone or in combination did not alter BDNF in the prefrontal cortex (p=0.37),eurotrophin-3
luoxetine
lanzapine
ood disorder
hippocampus (p=0.98) and amygdala (p=0.57) or NGF protein levels in the prefrontal cortex (p=0.72),
hippocampus (p=0.23) and amygdala (p=0.64), but NT-3 protein levels were increased by olanzapine
6mg/kg/ﬂuoxetine25mg/kgcombination in theprefrontal cortex (p=0.03), in thehippocampus (p=0.83)
and amygdala (p=0.88) NT-3 protein levels did not alter. Finally, these ﬁndings further support the
hypothesis that NT-3 could be involved in the effect of treatment with antipsychotic and antidepressant
combination in mood disorders.ipolar disorder (BD) is a prevalent condition in adults determining
signiﬁcant impairment in quality of life [27]. Bipolar depression
epresents a difﬁcult-to-treat and disabling form of depression.
tudies indicate that patients with BD spend more time in and take
onger to recover from the depressive phase than the manic phase
33,47].
Olanzapine (OLZ) has demonstrated efﬁcacy in the treat-
ent of acute bipolar mania [59,61–63,65] stabilizing effects
11,60,62,65,66] and has been found to improve depressive symp-
oms in patients with schizophrenia [58,64]. In a controlled study
f Shelton et al. [53] subjects with treatment-resistant depression
eceivedOLZalone,ﬂuoxetine (FLX) alone, or a combinationofboth.
he combination was associated with signiﬁcantly greater and
aster improvement thanwas either drug alone. In a critical review,
ountoulakis et al. [26] show that several practice guidelines dis-
gree on how best to initiate treatment of bipolar depression.Neurotrophic factors, as such, brain derived neurotrophic fac-
or (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT-3)
re critical regulators of the formation, survival, differentiation,
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and outgrowth of select peripheral and central neurons throughout
adulthood [32,51] and plasticity of neural networks [28,32,51].
Sincehowthe combinationofOLZandFLXmodulates stabilizing
effects centrally is little known, the present study was aimed to
investigate physiological effects of the combination of OLZ and FLX
on the BDNF, NT-3 and NGF protein levels in the prefrontal cortex,
hippocampus and amygdala.
Male adult Wistar rats (60 days old) were obtained from
UNESC (Universidade do Extremo Sul Catarinense, Criciúma, SC,
Brazil) breeding colony. They were housed ﬁve per cage with food
and water available ad libitum and were maintained on a 12-h
light/dark cycle (lights on at 7:00 a.m.). All experimental proce-
dures involving animals were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals and the
Brazilian Society for Neuroscience and Behavior (SBNeC) recom-
mendations for animal care and with approval by local Ethics
Committee under protocol number 510/2006.
Olanzapine (ZyprexaTM) and Fluoxetine (ProzacTM) were pro-
vided from Eli Lilly do Brasil Ltda, São Paulo, Brazil. Animals
Open access under the Elsevier OA license.received daily intraperitoneal injections of OLZ (3 or 6mg/kg), FLX
(12.5 or 25mg/kg) (n=10) or combination of bothdrugs for 28days.
All the drugswere dissolved in Tween1% solution (vehicle). Control
animals received vehicle (1.0ml/kg). After the chronic treatment
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he animals were killed by decapitation 24h after the last injection
nd prefrontal cortex, hippocampus and amygdala were immedi-
tely removed and stored at −70 ◦C for biochemical analysis.
BDNF, NT-3 and NGF levels in prefrontal cortex, hippocampus
nd amygdala were measured by sandwich-ELISA, according to the
anufacturer instructions (Chemicon, USA for BDNF and Millipore,
SA & Canada for NT-3 and NGF). Brieﬂy, rat prefrontal cortex, hip-
ocampus and amygdala were homogenized in phosphate buffer
olution (PBS) with protease inhibitor cocktail (Sigma). Microtiter
lates (96-well ﬂat-bottom) were coated for 24h with the samples
iluted 1:2 in sample diluent and standard curve ranged from7.8 to
00pg/ml of BNDF, NT-3 or NGF. The plates were then washed four
imes with sample diluent and a monoclonal anti-BNDF, anti-NT-3
r anti-NGF rabbit antibody (diluted 1:1000 in sample diluent) was
dded to eachwell and incubated for 3h at room temperature. After
ashing, a peroxidase conjugated anti-rabbit antibody (diluted
:1000) was added to each well and incubated at room temper-
ture for 1h. After addition of streptavidin-enzyme, substrate and
top solution, the amount of each neurotrophin was determined by
bsorbance in 450nm. The standard curve demonstrates a direct
elationship between Optical Density (OD) and the concentration.
otal proteinwasmeasuredby Lowry’smethodusingbovine serum
lbumin as a standard, as previously described by Lowry et al. [39].
All data are presented as mean± S.E.M. Differences among
xperimental groups in the assessment of BDNF,NGF andNT-3pro-
ein levelsweredeterminedbyone-wayANOVA, followedbyTukey
ost hoc testwhenANOVAwas signiﬁcant;p<0.05were considered
o be statistical signiﬁcant.
As depicted in Fig. 1A, the NT-3 protein levels did not alter in
he hippocampus (Fig. 1A; F(8–42) = 0.51; p=0.83) and amygdala
Fig. 1A; F(8–43) = 0.45; p=0.88) after treatment with olanzapine or
uoxetine alone or in combination. However treatment with olan-
apine at the dose of 6mg/kg in combination with ﬂuoxetine at the
ose of 25mg/kg we found an increase in NT-3 protein levels in
he prefrontal cortex (Fig. 1A; F(8–37) = 2.4; p=0.03); but olanzapine
r ﬂuoxetine treatment alone did alter NT-3 protein levels in the
refrontal cortex.
The BDNF and NGF protein levels are illustrated in Fig. 1B and
C, respectively. After treatment with olanzapine or ﬂuoxetine
lone or in combination, both BDNF and NGF protein levels did
ot alter in the prefrontal cortex (Fig. 1B; F(8–46) = 1.11; p=0.37;
ig. 1C; F(8–24) = 0.65; p=0.72), hippocampus (Fig. 1B; F(8–51) = 0.98;
=0.45; Fig. 1C; F(8–18) = 1.48; p=0.23) and amygdala (Fig. 1B;
(8–47) = 0.57; p=0.79; Fig. 1C; F(8–18) = 0.74; p=0.64).
In the present study we evaluated the effects of the antipsy-
hotic OLZ and of the antidepressant FLX (alone or in combination)
n the NT-3, BDNF and NGF protein levels in the rat brain. We
howed that chronic treatment with FLX and OLZ in combination
ncreased the NT-3 protein levels in the prefrontal cortex. Treat-
ent with FLX and OLZ alone or in combination did not alter BDNF
r NGF protein levels in the rat brain.
The hippocampus regulates hypothalamic–pituitary–adrenal
HPA) axis, and has connections with amygdala and prefrontal
ortex. In addition, brain imaging studies have indicated volumes
ltered of the hippocampus, prefrontal cortex or amygdala in
atients with major depression or bipolar disorder [14,20].
Several studies have highlighted the role of neurotrophins in
he pathophysiology and treatment of psychiatric disorders [24].
he BDNF, NT-3 and NGF promote survival and cellular plastic-
ty [4,38]. Reductions of BDNF have been found in serum humans
ith major depression, as well as in animal models [22,34], on the
ther hand, infusion of BDNF into dentate gyrus in rat hippocam-
us produces antidepressant effect [55]. Moreover, patients with
chizophrenia and bipolar disorder showed reduced serum BDNF
evels in relation to healthy volunteers [17,49,50], and it is known
hat antipsychotic, as well as mood stabilizers treatment are seemsLetters 497 (2011) 99–103
to alter levels of BDNF in rat hippocampus, in plasma and serum
of patients with psychiatric disorders [9,29,49,50].In the present
ﬁndings we showed that treatment with FLX and OLZ alone or in
combination did not alter BDNF protein levels in the prefrontal cor-
tex, hippocampus or amygdala. Our investigation did not conﬁrm
previous studies showed by other authors, who reported alteration
in BDNF after treatmentwith FLX or OLZ. Lee et al. [35] showed that
OLZ treatment (10–100M) increased basal BDNF gene promoter
activity in a dose dependent manner and increased protein levels
at high dose. In addition, OLZ increased BDNF levels in the cortex
and hippocampus [18] and frontal cortex [10]. Also, FLX adminis-
tration increased BDNF mRNA levels in the nucleus accumbens and
hippocampus [42,43]. We cannot explain the reason for this dif-
ferent result, but similar discrepancies have been observed by the
other author. In fact, plasma BDNF levels did not alter after 8 weeks
of treatment with OLZ [31,67]. FLX also did not alter BDNF mRNA
isoforms in the rat hippocampus [5,19]. FLX (10mg/kg) increased
BDNF protein levels in the frontal cortex, but not in the hippocam-
pus, amygdala, olfactory, and brain stem [10]. Other study showed
still that FLX treatment decrease BDNF mRNA expression in the rat
hippocampus [41]. In other studies, OLZ decreased BDNF in the hip-
pocampus and frontal cortex [7], anddid not alleviate the decreases
in RNA expression of BDNF and NGF produced by neonatal quinpi-
role treatment [15]. Furthermore, both BDNF and NGF seem to be
activity-dependent [36]. In the present data, we did not see alter-
ations in BDNF or NGF protein levels in the rat brain, suggesting
that the effects by FLX and OLZ on the BDNF and NGF levels were
not modulated by these neurotrophins, because they are activity-
dependent.
NGF is very important to neuronal survival, neurite outgrowth
and synapse formation [4] and has been shown an association
between NGF and mood disorders or psychiatric diseases. In fact,
NGFwas found to be decreased in plasma in BDpatientswhen com-
pared to that seen with controls and BD individuals in mania had
lower NGF levels than euthymic patients or controls [12]. NGF also
has been found decreased in plasma, liquor or postmortem brains
of schizophrenic patients [3,13,23]. On the other hand, the antipsy-
chotics, haloperidol, chlorpromazine, risperidone and OLZ reduced
BDNF and NGF protein levels in the striatum and hippocampus
[48], in this study the authors showed that second-generation
antipsychotics compared to ﬁrst-generation antipsychotics are
less deleterious on neurotrophic factors in the brain. In contrast,
Parikn et al. [46], demonstrated that OLZ, but not the antipsy-
chotic risperidone increased levels of NGF in the hippocampus.
Additionally, administration of OLZ for 29 days at the doses of 3
and 15mg/kg increased BDNF in the hippocampus and occipital
cortex [7]. Discrepancies between studies may be related to route
of drug administration.Little is known about antidepressants and
NGF. In the present we did not show an alteration on NGF protein
levels after treatment with FLX alone or in combination with OLZ.
The antidepressants, amitriptyline andparoxetine also did not alter
NGF serum concentrations from depressed patients [30]. However,
it was recently demonstrated that intranasal NGF had signiﬁcant
antidepressant effects on animal models of depression [54]. On
the other hand, NGF was reduced in brain regions of the Flinders
Sensitive Line rat, a genetic animalmodel of depression [6]. In addi-
tion, anescitalopram-dependentNGFreduction in stressed ratswas
detectable in the cortex, but not in the frontal cortex, cerebellum
and serum [52]. Moreover, the antidepressant ﬂuvoxamine poten-
tiated the NGF-induced neurite outgrowth [44] and desipramine or
ﬂuoxetine for 48h elevated the NGF mRNA expression [37] in PC12
cells.NT-3 is a neurotrophin that plays key roles in neuronal sur-
vival, differentiation, connectivity and plasticity [32,51].Moreover,
human studies have demonstrated participation of NT-3 in the
pathophysiology of stress, major depression and BD [25,34,56].
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n=10). Bars represent means± S.E.M. *p<0.05 vs. saline according to ANOVA follow
nterestingly, the present data shows that the combined admin-
stration of FLX and OLZ increased NT-3 protein levels in the
refrontal cortex. Lesions of the prefrontal cortex are associated
ith development of depression or aggression [8].
Serum NT-3 levels in drug-free and medicated patients with
D during manic and depressive episodes were increased when
ompared with controls [25]. A study conducted by Otsuki et al.
45] showed reduced expression levels of NT-3 mRNAs, but not in
DNF, NGF and neurotrophin-4 mRNAs in peripheral white blood
ells in patientswithmajor depressive disorder in a current depres-
ive state, but not in a remissive state, suggesting that the changes
n the NT-3 mRNAs might be state-dependent and associated withd NGF (C) protein levels in the rat prefrontal cortex, hippocampus and amygdala
y Tukey post hoc test.
the pathophysiology ofmajor depression. Our ﬁndings showed that
FLX plus OLZ increased NT-3 protein levels, but not BDNF and NGF,
suggesting that treatment with these drugs may be important to
current depressive state. The gene expression for NT-3 was not
affected by single or repeated administration of antidepressants
drugs, including FLX [16]. Our study also showed that FLX alone
did not alter NT-3 protein levels, but in combination with OLZ
increased NT-3 protein levels. In fact, the combination of OLZ and
FLX produces signiﬁcantly greater and faster improvement than
either drug alone in subjects with treatment-resistant depression
[40]. Importantly, FLX is a potent hepatic enzyme inhibitor, but
there was not found differences in hepatic enzymes in patients
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ith bipolar depressive episode treated with OLZ/FLX in combi-
ation [58], thus pharmacokinetic interaction may be involved in
sychopharmacological effects.
Some studies have shown an association between neu-
otrophins and glucocorticoids [57]. It was shown an increase
f NGF and NT-3 mRNA in the hippocampus by glucocorticoids,
robably as a compensatory response to stress-induced damage
56]. Additionally a study showed that glucocorticoids exert bipha-
ic effects on neuronal mitochondrial dynamics, with low levels
otentiating and chronic high levels attenuating various aspects
f mitochondrial function [21]. Studies from our group recently
emonstrated that FLX and OLZ alone or in combination altered
he creatine kinase and citrate synthase activities [1,2], which are
nvolved with energy metabolism.
In conclusion, the present ﬁndings suggest that NT-3 may be
nvolved in the therapeutic action of olanzapine/ﬂuoxetine com-
ination in mood disorders. Finally, future studies evaluating the
ombination of behavioral, neurochemical and dosing the plas-
atic levels of FLX and OLZ, would be necessary and opportune
o expand the present result.
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